Zafgen (ZFGN) reports Q4 loss per share of 39c, to suspend plans to file IND application for ZGN-1258
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates
March 11, 2019 4:05 PM EDTRecently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061
Updates on progress preparing for FDA Type A meeting for ZGN-1061
Suspends IND filing plans for ZGN-1258 based on nonclinical finding in long-term toxicology studies
Expanded executive team with highly experienced drug development leader, Dr. Priya Singhal, as Head of Research and Development
Company to host conference call today at 5:00 p.m. ET
BOSTON, March 11, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:... More
